The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
暂无分享,去创建一个
[1] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[2] G. Linette,et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Ratain,et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.
[4] Prahlad T. Ram,et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. , 2010, Cancer research.
[5] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[6] Jonathan Chernoff,et al. Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .
[7] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[8] K. Flaherty,et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Chatfield,et al. BRAF mutation by age-decade and body mass index in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. Dhomen,et al. BRAF signaling and targeted therapies in melanoma. , 2009, Hematology/oncology clinics of North America.
[11] David P. Davis,et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. , 2006, Cancer research.
[12] D. Pinkel,et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.
[13] J. Hansson,et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site , 2008, Molecular oncology.
[14] K. Flaherty,et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. , 2010 .
[15] K. Bloom,et al. Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. LoRusso,et al. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer , 2005 .
[18] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Iafrate,et al. BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.
[20] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[22] J. Lundeberg,et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.
[23] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] V. Gebski,et al. Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[26] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[27] J. Stockman,et al. Distinct Sets of Genetic Alterations in Melanoma , 2007 .
[28] M. Trivett,et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.
[29] M. Brown,et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .
[30] Steven Whittaker,et al. Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies , 2010, Science Translational Medicine.
[31] J. Becker,et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.
[32] P. Edwards,et al. Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.
[33] W. Franklin,et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Chu,et al. Frequency of mutations associated with targeted therapy in malignant melanoma patients. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Mann,et al. Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] C. Garbe,et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.
[38] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[39] F. Mascarelli,et al. Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway* , 2003, Journal of Biological Chemistry.
[40] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[41] K. Flaherty,et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Engelman,et al. Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers , 2011, Oncotarget.
[43] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[44] Ultan McDermott,et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.
[45] Jane Fridlyand,et al. Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.
[46] A. Aplin,et al. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. , 2010, Cancer research.
[47] R. Millikan,et al. Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma , 2007, Cancer Epidemiology Biomarkers & Prevention.
[48] C. Ng,et al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] V. Sondak,et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.
[50] P. Hersey,et al. MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720 , 2010, Clinical Cancer Research.
[51] C. Marshall,et al. B-RAF is a therapeutic target in melanoma , 2004, Oncogene.
[52] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] A. Hauschild,et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] M. Hidalgo,et al. Novel targets in solid tumors: MEK inhibitors. , 2006, Clinical advances in hematology & oncology : H&O.
[55] D. Silvers,et al. GAB2 Amplifications Refine Molecular Classification of Melanoma , 2009, Clinical Cancer Research.
[56] K. Flaherty,et al. Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. , 2010 .
[57] R. Dummer,et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. , 2008 .
[58] J. Infante,et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] K. Flaherty. Is it good or bad to find a BRAF mutation? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[61] Hong Wu,et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.
[62] K. Flaherty,et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. , 2008, Cancer research.
[63] P. Hersey,et al. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria , 2003, Oncogene.
[64] S. Ariyan,et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 , 2010, Journal of Translational Medicine.
[65] R. Kefford,et al. Targeting BRAF for patients with melanoma , 2010, British Journal of Cancer.
[66] A. Weeraratna,et al. Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010 , 2011, Pigment cell & melanoma research.
[67] K. Flaherty,et al. Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.